Tecvayli (teclistamab-cqyv)
Named-patient access overview. Tecvayli is coordinated by Reserve Meds for international patients through cross-border sourcing coordinated with your treating doctor.
Ask about Tecvayli
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
About Tecvayli
Tecvayli (teclistamab-cqyv) is a BCMA x CD3 bispecific T-cell engager developed by Janssen Biotech (a Johnson and Johnson company) in collaboration with Genmab. By simultaneously binding B-cell maturation antigen (BCMA) on myeloma cells and CD3 on cytotoxic T cells, it brings the patient's own T cells into direct contact with the tumour to drive immune-mediated killing.
Tecvayli received accelerated FDA approval in October 2022 for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. It is administered as a subcutaneous (SC) injection and requires a step-up dosing regimen during initiation to mitigate the risk of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
Because of the boxed warnings for CRS and neurologic toxicity, initiation and step-up doses must be administered in a setting equipped for inpatient observation and rapid intervention. Tecvayli is distributed in the US under a Risk Evaluation and Mitigation Strategy (REMS) programme. International access via Named Patient Program or personal-import pathways is coordinated by Reserve Meds for patients in markets where Tecvayli is not yet locally registered.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
How Reserve Meds coordinates Tecvayli
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Tecvayli for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Tecvayli is sourced from a US-licensed pharmaceutical wholesale partner with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Clinical trials and expanded access
On 17 October 2026 we searched ClinicalTrials.gov, the clinical study registry of the US National Library of Medicine, for studies that list teclistamab as an intervention. The search found studies that are recruiting or not yet recruiting. See the current list on ClinicalTrials.gov.
Whether a patient can join a trial or an expanded access program is decided by the study team or the manufacturer, together with the treating doctor. Reserve Meds does not run trials or supply investigational medicines. We can help you and your doctor read a listing and understand the route.
Access by country
Reserve Meds publishes a detailed country deep-dive for Tecvayli in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), how quotes work, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Tecvayli
Send us the medicine and your country. We reply within one business day with case-specific feasibility, timeline, and a formal quote.
Reserve Meds coordinates Tecvayli through Johnson and Johnson portfolio overview for the full cross-border catalog.
Frequently asked questions
How can I get Tecvayli if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Tecvayli for patients through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Tecvayli through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Tecvayli. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Tecvayli through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Tecvayli to a patient?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Tecvayli to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Tecvayli cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Tecvayli?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.